These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 14676628)

  • 41. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
    Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
    Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.
    Tefferi A; Levine RL; Lim KH; Abdel-Wahab O; Lasho TL; Patel J; Finke CM; Mullally A; Li CY; Pardanani A; Gilliland DG
    Leukemia; 2009 May; 23(5):900-4. PubMed ID: 19262599
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Treatment of systemic mastocytosis].
    Marrache F; Mémain N; Bonté I; Barete S; Casassus P; de Gennes C; Fain O; Hermine O; Lortholary O
    Rev Med Interne; 2003 Sep; 24(9):594-601. PubMed ID: 12951180
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement.
    Williams C; Kalra S; Nath U; Bown N; Wilson V; Wilkins BS; Neylon AJ
    J Clin Pathol; 2008 May; 61(5):677-80. PubMed ID: 18256119
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.
    Helbig G; Moskwa A; Hus M; Piszcz J; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Seferyńska I; Hałasz M; Woszczyk D; Markiewicz M; Krzemień S
    Hematol Oncol; 2010 Jun; 28(2):93-7. PubMed ID: 19728396
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pure red cell aplasia associated with imatinib-treated FIP1L1-PDGFRA positive chronic eosinophilic leukemia.
    Tanaka H; Iwato K; Asou H; Kimura A
    Intern Med; 2010; 49(12):1195-200. PubMed ID: 20558942
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].
    Li B; Zhang GS; Dai CW; Pei MF
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.
    Martinelli G; Malagola M; Ottaviani E; Rosti G; Trabacchi E; Baccarani M
    Haematologica; 2004 Feb; 89(2):236-7. PubMed ID: 15003901
    [No Abstract]   [Full Text] [Related]  

  • 49. [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].
    Menif S; Ben Romdhane N; Hafsia R
    Rev Med Interne; 2008 Jan; 29(1):65-7. PubMed ID: 18036706
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis.
    McPherson T; Cowen EW; McBurney E; Klion AD
    Br J Dermatol; 2006 Oct; 155(4):824-6. PubMed ID: 16965435
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Kit Mutations: New Insights and Diagnostic Value.
    Falchi L; Verstovsek S
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome].
    Martinaud C; Souraud JB; Cournac JM; Pons S; Ménard G; de Jaureguiberry JP; Brisou P
    Rev Med Interne; 2011 May; 32(5):e66-8. PubMed ID: 20633965
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The hypereosinophilic syndromes: current concepts and treatments.
    Gleich GJ; Leiferman KM
    Br J Haematol; 2009 May; 145(3):271-85. PubMed ID: 19243381
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Imatinib for systemic mast-cell disease.
    Pardanani A; Elliott M; Reeder T; Li CY; Baxter EJ; Cross NC; Tefferi A
    Lancet; 2003 Aug; 362(9383):535-6. PubMed ID: 12932387
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
    Gotlib J; Gerds AT; Bose P; Castells MC; Deininger MW; Gojo I; Gundabolu K; Hobbs G; Jamieson C; McMahon B; Mohan SR; Oehler V; Oh S; Padron E; Pancari P; Papadantonakis N; Pardanani A; Podoltsev N; Rampal R; Ranheim E; Rein L; Snyder DS; Stein BL; Talpaz M; Thota S; Wadleigh M; Walsh K; Bergman MA; Sundar H
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1500-1537. PubMed ID: 30545997
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Isolated lymphadenopathy as the first presentation of systemic mastocytosis--description of two cases].
    Kinkor Z; Síma R; Skálová A; Boudová L; Peková S; Dvoráková D; Dĕdic K; Kracík M; Janousek M; Michal M
    Cesk Patol; 2006 Jan; 42(1):34-8. PubMed ID: 16506600
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Imatinib mesylate in the treatment of hematologic malignancies.
    Piccaluga PP; Rondoni M; Paolini S; Rosti G; Martinelli G; Baccarani M
    Expert Opin Biol Ther; 2007 Oct; 7(10):1597-611. PubMed ID: 17916051
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders.
    Gotlib J; Akin C
    Semin Hematol; 2012 Apr; 49(2):128-37. PubMed ID: 22449623
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
    La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
    Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Efficiency of imatinib in polyserositis revealing a FIP1L1-PDGFRA-negative hypereosinophilic syndrome].
    Green L; Kahn JE; Dufour JF; Le Scanff J; Charhon A; Broussolle C; Sève P
    Rev Med Interne; 2010 Apr; 31(4):305-8. PubMed ID: 20167399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.